First- and Second-Generation Antipsychotics

McEvoy JP . Antipsychotic drugs. In: Squire LR , editor. Encyclopedia of neuroscience. Vol 1. Oxford (GB): Academic Press; 2009. p 487–492.

McEvoy JP Hogarty GE Steingard S. Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48:739–745.

Lieberman JA Stroup TS McEvoy JP . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.

Beasley CM Jr Stauffer BL Liu-Seifert H . All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: An integrated analysis. J Clin Psychopharmacol. 2007;27:252–258.

Tiihonen J Wahlbeck K Lönnqvist J . Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalizations due to schizophrenia and schizoaffective disorder: Observational follow-up study. BMJ. 2006;333:224.

Geddes J Freemantle N Harrison P . Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ. 2000;321:1371–1376.

Leucht S Corves C Arbter D . Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet. 2009;373(9657):31–41. [Epub 2008 Dec 6.].

Jones PB Barnes TR Davies L . Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–1087.

Stroup TS Lieberman JA McEvoy JP . Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am J Psychiatry. 2007;164:415–427.

Lieberman JA Stroup TS McEvoy JP . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.

Jones PB Barnes TRE Davies L . Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079–1087.

Martin JLR Pérez V Sacristán M . Meta-analysis of drop-out rates in randomized clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. Eur Psychiatry. 2006;21(1):11–20.

Davis JM Chen N. Old versus new: Weighing the evidence between the first-and second-generation antipsychotics. Eur Psychiatry. 2005;20(1):7–14.

Correll CU Leucht S Kane JM . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425.

Manschreck TC Boshes RA . The CATIE schizophrenia trial: Results, impact, controversy. Harv Rev Psychiatry. 2007;15(5):245–258.

Sweet RA Pollock BG Mulsant BH . Pharmacologic profile of perphenazine's metabolites. J Clin Psychopharmacol. 2000;20(2):181–187.

Diaz E Neuse E Sullivan MC . Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65(3):354–360.

Geddes J Freemantle N Harrison P . Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371–1376.

Woodward ND Purdon SE Meltzer HY . A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457–472.

Woodward ND Purdon SE Meltzer HY . A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophr Res 2007;89(1–3):211–224.

Margolese HC Chouinard G Kolivakis TT . Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: Pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–547.

McEvoy JP Lieberman JA Stroup TS . Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.

Perez-Iglesias R Crespo-Facorro B Martinez-Garcia O . Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008;99(1–3):13–22. [Epub 2007 Dec 3.].

Swartz MS Wagner HR Swanson JW . The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. Schizophr Res. 2008;100(1–3):39–52.

Schooler N Rabinowitz J Davidson M . Risperidone and haloperidol in first episode psychosis: A long-term randomized trial. Am J Psychiatry. 2005;162:947–953.

Gaebel W Riesbeck M Wölwer W . Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007;68:1763–1774.

Lieberman JA Tollefson GD Charles C . Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62:361–370.

Sikich L Frazier JA McClellan J . Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420–1431. [Epub 2008 Sep 15.] Erratum in: Am J Psychiatry. 2008;165(11):1495.

Beasley CM Jr Stauffer BL Liu-Seifert H . All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: An integrated analysis. J Clin Psychopharmacol. 2007;27:252–258.

Tiihonen J Wahlbeck K Lönnqvist J . Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalizations due to schizophrenia and schizoaffective disorder: Observational follow-up study. BMJ. 2006;333:224.

Stroup TS Lieberman JA McEvoy JP . Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE Study. Am J Psychiatry. 2007;164:415–427.

Perez-Iglesias R Crespo-Facorro B Martinez-Garcia O . Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008;99(1–3):13–22. [Epub 2007 Dec 3.].

Perez-Iglesias R Mata I Pelayo-Teran JM . Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res. 2009;107(2–3):115–121. [Epub 2008 Nov 6.].

McEvoy JP Lieberman JA Perkins DO . Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050–1060.

Zipursky RB Gu H Green AI . Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537–543.

Bleakley S Olofinjana O Taylor D. Which antipsychotics would mental health professionals take themselves? Psychiatric Bull. 2007;31:94–96.